Home/Pipeline/VRB-101 (Oral)

VRB-101 (Oral)

Obesity

Phase 2Active

Key Facts

Indication

Obesity

Phase

Phase 2

Status

Active

Company

Verdiva Bio

About Verdiva Bio

Verdiva Bio is a well-funded private biotech targeting the massive obesity and cardiometabolic market with a differentiated pipeline of peptide-based therapies. Its lead asset, VRB-101, is an oral, once-weekly GLP-1 analog (ecnoglutide) currently in Phase 2b development, supported by a proprietary oral absorption enhancer. The company is also developing amylin-based candidates and combinations, positioning itself in the next wave of incretin/amylin therapies with a focus on oral and convenient dosing. Backed by over $410M in Series A financing and a seasoned leadership team, Verdiva aims to become a key player in the evolving metabolic disease landscape.

View full company profile

Therapeutic Areas

Obesity Cardiometabolic Disorders

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active
VIAL-INHBE (siRNA)	VIAL Dermatology CRO	Phase 1	Active